Pharma Pulse 7/8/24: New AI Tech Spurs Excitement/Concerns Among Private-Credit Managers, Future Perspectives on Atopic Dermatitis Treatment & more

Looking Ahead to Cardinal Health's Biosimilar Pipeline

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses what to expect from Cardinal Health's biosimilars pipeline.

Future Perspectives on Atopic Dermatitis Treatment

Focusing on the future treatment landscape of atopic dermatitis, Dr Eichenfield discusses current unmet needs and highlights standout studies and presentations from the 2024 AAD Annual Meeting.

New AI Technology Spurs Excitement and Concerns Among Private-Credit Managers

Unease about data bias and job security as the use of generative AI ramps up could temper enthusiasm among private lenders.

BenevolentAI: Leadership Team Change

BenevolentAI announced a change to its Executive Leadership Team following the recent Annual General Meeting and the election of a new Board of Directors.

@jakegoodmanmd on Threads

I’m a physician who treats mental health, and I just saw Inside Out 2.

Wow.

The way that they conceptualized anxiety was masterful. They showed that anxiety is NOT this scary villain who needs to be shunned from the rest of your emotions. Instead, anxiety keeps us safe and pushes us to plan for the future. Problems can arise when anxiety takes the wheel for too long, just like with any other emotion. I wish this movie existed when we were younger. 10/10.

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs